JP2022536854A5 - - Google Patents
Info
- Publication number
- JP2022536854A5 JP2022536854A5 JP2021575320A JP2021575320A JP2022536854A5 JP 2022536854 A5 JP2022536854 A5 JP 2022536854A5 JP 2021575320 A JP2021575320 A JP 2021575320A JP 2021575320 A JP2021575320 A JP 2021575320A JP 2022536854 A5 JP2022536854 A5 JP 2022536854A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- patient
- inhibitor
- cdk4
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962863153P | 2019-06-18 | 2019-06-18 | |
| US62/863,153 | 2019-06-18 | ||
| US201962907375P | 2019-09-27 | 2019-09-27 | |
| US62/907,375 | 2019-09-27 | ||
| PCT/US2020/038557 WO2020257536A1 (en) | 2019-06-18 | 2020-06-18 | Patient selection for enhancement of anti-tumor immunity in cancer patients |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022536854A JP2022536854A (ja) | 2022-08-19 |
| JP2022536854A5 true JP2022536854A5 (enExample) | 2023-06-27 |
| JP7812232B2 JP7812232B2 (ja) | 2026-02-09 |
Family
ID=74040931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021575320A Active JP7812232B2 (ja) | 2019-06-18 | 2020-06-18 | 癌患者における抗腫瘍免疫の増強のための患者選択 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220175787A1 (enExample) |
| EP (1) | EP3986410A4 (enExample) |
| JP (1) | JP7812232B2 (enExample) |
| KR (1) | KR20220024540A (enExample) |
| CN (1) | CN114222577A (enExample) |
| AU (1) | AU2020296087A1 (enExample) |
| CA (1) | CA3143339A1 (enExample) |
| TW (1) | TW202114684A (enExample) |
| WO (1) | WO2020257536A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME03557B (me) * | 2013-03-15 | 2020-07-20 | G1 Therapeutics Inc | Privremena zaštiтa normalnih ćelija током hemoterapije |
| KR20190092478A (ko) | 2016-12-05 | 2019-08-07 | 쥐원 쎄라퓨틱스, 인크. | 화학요법 레지멘 동안의 면역 반응의 보존 |
| KR20230012547A (ko) | 2020-05-19 | 2023-01-26 | 쥐원 쎄라퓨틱스, 인크. | 의학적 장애의 치료를 위한 시클린-의존성 키나제 억제 화합물 |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
| EP4353231A4 (en) * | 2021-06-10 | 2025-05-28 | OnQuality Pharmaceuticals China Ltd. | Compound and method for treating chemotherapy-associated gastrointestinal adverse effects |
| EP4362948A4 (en) * | 2021-07-01 | 2025-05-07 | Pharmacosmos Holding A/S | Combination treatments in patients with advanced and/or metastatic trop-2 overexpressed cancers |
| WO2023064913A1 (en) * | 2021-10-14 | 2023-04-20 | Wisconsin Alumni Research Foundation | K17 as a biomarker for tumor response to immunotherapy |
| CN115019880B (zh) * | 2022-05-05 | 2024-01-09 | 中山大学附属第一医院 | 一种肝癌预后模型及其构建方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX338327B (es) | 2010-10-25 | 2016-04-12 | G1 Therapeutics Inc | Inhibidores de cdk. |
| WO2014144325A1 (en) | 2013-03-15 | 2014-09-18 | President And Fellows Of Harvard College | Methods and compositions for improving detection and/or capture of a target entity |
| ME03557B (me) | 2013-03-15 | 2020-07-20 | G1 Therapeutics Inc | Privremena zaštiтa normalnih ćelija током hemoterapije |
| WO2016126889A1 (en) * | 2015-02-03 | 2016-08-11 | G1 Therapeutics, Inc. | Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy |
| US11865176B2 (en) * | 2016-11-08 | 2024-01-09 | Dana-Farber Cancer Institute, Inc. | Compositions and methods of modulating anti-tumor immunity |
| KR20190092478A (ko) * | 2016-12-05 | 2019-08-07 | 쥐원 쎄라퓨틱스, 인크. | 화학요법 레지멘 동안의 면역 반응의 보존 |
| EP3585389A4 (en) * | 2017-02-22 | 2020-12-23 | G1 Therapeutics, Inc. | EGFR-CAUSED CANCER TREATMENT WITH LESS SIDE EFFECTS |
| US20200377599A1 (en) * | 2017-11-30 | 2020-12-03 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for treating cancer |
| US10122265B1 (en) | 2018-01-03 | 2018-11-06 | Intel Corporation | Reducing electromagnetic interference in switching regulators |
| WO2023034336A2 (en) * | 2021-08-30 | 2023-03-09 | G1 Therapeutics, Inc. | Improved treatments for advanced/metastatic cancers with checkpoint inhibitor resistance or resistance susceptibility |
-
2020
- 2020-06-18 TW TW109120659A patent/TW202114684A/zh unknown
- 2020-06-18 AU AU2020296087A patent/AU2020296087A1/en not_active Abandoned
- 2020-06-18 JP JP2021575320A patent/JP7812232B2/ja active Active
- 2020-06-18 CN CN202080056941.0A patent/CN114222577A/zh active Pending
- 2020-06-18 EP EP20825571.1A patent/EP3986410A4/en active Pending
- 2020-06-18 CA CA3143339A patent/CA3143339A1/en active Pending
- 2020-06-18 KR KR1020227001251A patent/KR20220024540A/ko not_active Ceased
- 2020-06-18 WO PCT/US2020/038557 patent/WO2020257536A1/en not_active Ceased
-
2021
- 2021-12-17 US US17/554,940 patent/US20220175787A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022536854A5 (enExample) | ||
| Park et al. | Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer | |
| Sen et al. | Combination treatment of the oral CHK1 inhibitor, SRA737, and low-dose gemcitabine enhances the effect of programmed death ligand 1 blockade by modulating the immune microenvironment in SCLC | |
| EP3903828A1 (en) | Combination of antibody-drug conjugate and kinase inhibitor | |
| JP7564122B2 (ja) | 光免疫療法のための方法および関連バイオマーカー | |
| TW202034959A (zh) | 抗體-藥物結合物與parp抑制劑之組合 | |
| Ma et al. | Enhanced immunotherapy of SM5-1 in hepatocellular carcinoma by conjugating with gold nanoparticles and its in vivo bioluminescence tomographic evaluation | |
| Wakasaki et al. | Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma | |
| Barot et al. | Recent advancement in targeted therapy and role of emerging technologies to treat cancer | |
| JP2015514113A (ja) | 単一特異性および二重特異性抗ｉｇｆ−１ｒおよび抗ｅｒｂｂ３抗体の用法および用量 | |
| ten Tije et al. | Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial | |
| RU2016141385A (ru) | Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf | |
| EP3710434A1 (en) | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms | |
| CN114340679A (zh) | 用于治疗对pd-1/pd-l1信号传导抑制剂无应答的癌症的方法和药物 | |
| US20210128609A1 (en) | Oncology treatments using zinc agents | |
| Candelaria et al. | Lack in Efficacy for Imatinib Mesylate as Second-Line Treatment of Recurrent or Metastatic Cervical Cancer Expressing Platelet-Derived Growth Factor Receptor a | |
| Qin et al. | CD19-targeted HSP90 inhibitor nanoparticle combined with TKIs reduces tumor burden and enhances T-cell immunity in murine B-cell malignancies | |
| JP2021509679A5 (enExample) | ||
| JP2021073203A (ja) | Ｈｅｒ２陽性転移性乳癌の治療方法 | |
| CA3225489A1 (en) | Compositions and methods for treatment of cancer | |
| JP7829491B2 (ja) | ６－チオ－ｄＧ、チェックポイント阻害剤および放射線療法を使用するがんの逐次処置 | |
| US20250368714A1 (en) | Treatment of cancer | |
| Thomas et al. | Randomized multicentric phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer: GFPC 99-01 study (Groupe français de pneumo-cancérologie) | |
| Piatek et al. | Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors | |
| JP2024516970A5 (enExample) |